SG10201705285SA - Antisense oligonucleotides - Google Patents

Antisense oligonucleotides

Info

Publication number
SG10201705285SA
SG10201705285SA SG10201705285SA SG10201705285SA SG10201705285SA SG 10201705285S A SG10201705285S A SG 10201705285SA SG 10201705285S A SG10201705285S A SG 10201705285SA SG 10201705285S A SG10201705285S A SG 10201705285SA SG 10201705285S A SG10201705285S A SG 10201705285SA
Authority
SG
Singapore
Prior art keywords
antisense oligonucleotides
present
relates
antisense
modulates
Prior art date
Application number
SG10201705285SA
Other languages
English (en)
Inventor
Guccione Ernest
Wee Keng Boon Dave
Bertoletti Antonio
Original Assignee
Agency Science Tech & Res
Lion Tcr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency Science Tech & Res, Lion Tcr filed Critical Agency Science Tech & Res
Priority to SG10201705285SA priority Critical patent/SG10201705285SA/en
Priority to JP2019572710A priority patent/JP7284718B2/ja
Priority to US16/626,395 priority patent/US12188016B2/en
Priority to PCT/SG2018/050313 priority patent/WO2019004939A1/en
Priority to SG11201911704UA priority patent/SG11201911704UA/en
Priority to KR1020207000349A priority patent/KR20200035937A/ko
Priority to AU2018291556A priority patent/AU2018291556B2/en
Priority to CN201880043866.7A priority patent/CN111630167B/zh
Priority to EP18823314.2A priority patent/EP3645724A4/en
Priority to CA3066035A priority patent/CA3066035A1/en
Publication of SG10201705285SA publication Critical patent/SG10201705285SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/33—Alteration of splicing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
SG10201705285SA 2017-06-27 2017-06-27 Antisense oligonucleotides SG10201705285SA (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
SG10201705285SA SG10201705285SA (en) 2017-06-27 2017-06-27 Antisense oligonucleotides
JP2019572710A JP7284718B2 (ja) 2017-06-27 2018-06-27 T細胞の機能を調節するためのアンチセンスオリゴヌクレオチド
US16/626,395 US12188016B2 (en) 2017-06-27 2018-06-27 Antisense oligonucleotides for modulating the function of a T cell
PCT/SG2018/050313 WO2019004939A1 (en) 2017-06-27 2018-06-27 ANTISENSE OLIGONUCLEOTIDES FOR MODULATING THE FUNCTION OF A LYMPHOCYTE T
SG11201911704UA SG11201911704UA (en) 2017-06-27 2018-06-27 Antisense oligonucleotides for modulating the function of a t cell
KR1020207000349A KR20200035937A (ko) 2017-06-27 2018-06-27 T 세포의 기능을 조절하기 위한 안티센스 올리고뉴클레오티드
AU2018291556A AU2018291556B2 (en) 2017-06-27 2018-06-27 Antisense oligonucleotides for modulating the function of a T cell
CN201880043866.7A CN111630167B (zh) 2017-06-27 2018-06-27 用于调节t细胞功能的反义寡核苷酸
EP18823314.2A EP3645724A4 (en) 2017-06-27 2018-06-27 ANTISENSE OLIGONUCLEOTIDES FOR MODULATING THE FUNCTION OF A T-CELL
CA3066035A CA3066035A1 (en) 2017-06-27 2018-06-27 Antisense oligonucleotides for modulating the function of a t cell

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SG10201705285SA SG10201705285SA (en) 2017-06-27 2017-06-27 Antisense oligonucleotides

Publications (1)

Publication Number Publication Date
SG10201705285SA true SG10201705285SA (en) 2019-01-30

Family

ID=64742433

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201705285SA SG10201705285SA (en) 2017-06-27 2017-06-27 Antisense oligonucleotides
SG11201911704UA SG11201911704UA (en) 2017-06-27 2018-06-27 Antisense oligonucleotides for modulating the function of a t cell

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201911704UA SG11201911704UA (en) 2017-06-27 2018-06-27 Antisense oligonucleotides for modulating the function of a t cell

Country Status (9)

Country Link
US (1) US12188016B2 (cg-RX-API-DMAC7.html)
EP (1) EP3645724A4 (cg-RX-API-DMAC7.html)
JP (1) JP7284718B2 (cg-RX-API-DMAC7.html)
KR (1) KR20200035937A (cg-RX-API-DMAC7.html)
CN (1) CN111630167B (cg-RX-API-DMAC7.html)
AU (1) AU2018291556B2 (cg-RX-API-DMAC7.html)
CA (1) CA3066035A1 (cg-RX-API-DMAC7.html)
SG (2) SG10201705285SA (cg-RX-API-DMAC7.html)
WO (1) WO2019004939A1 (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015367378A1 (en) 2014-12-17 2017-06-15 Proqr Therapeutics Ii B.V. Targeted RNA editing
US11576932B2 (en) * 2016-03-31 2023-02-14 Lion Tcr Pte. Ltd. Non-activated t cells expressing exogenous virus-specific T cell receptor (TCR)
EP3475424A1 (en) 2016-06-22 2019-05-01 ProQR Therapeutics II B.V. Single-stranded rna-editing oligonucleotides
WO2018041973A1 (en) 2016-09-01 2018-03-08 Proqr Therapeutics Ii B.V. Chemically modified single-stranded rna-editing oligonucleotides
GB201808146D0 (en) 2018-05-18 2018-07-11 Proqr Therapeutics Ii Bv Stereospecific Linkages in RNA Editing Oligonucleotides
CN112840026B (zh) * 2018-10-18 2025-01-14 施能康公司 抑制tigit基因表达的组合物和方法
US20220177894A1 (en) * 2019-04-02 2022-06-09 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for immunotherapy
CN109988842B (zh) * 2019-04-19 2022-12-06 上海吉玛制药技术有限公司 一种寡核苷酸标记探针原位检测pdl1的试剂组与应用
EP3959313A4 (en) * 2019-04-26 2023-09-27 Stoke Therapeutics, Inc. METHODS AND COMPOSITIONS FOR MODULATING SPLICING OF ALTERNATIVE INTRONS
CN110157705B (zh) * 2019-05-16 2021-06-18 苏州安天圣施医药科技有限公司 在pdcd1基因表达的剪接水平抑制pd-1信号的反义寡核苷酸及其筛选方法与应用
US20220380774A1 (en) * 2019-05-20 2022-12-01 Olix Pharmaceuticals, Inc. Asymmetric sirna inhibiting expression of pd-1
JP7337373B2 (ja) * 2019-07-29 2023-09-04 サイアス株式会社 抗原特異的t細胞の製造方法
EP4076476A4 (en) * 2019-12-17 2023-11-22 The General Hospital Corporation MODIFIED IMMUNE CELLS WITH REDUCED TOXICITY AND THEIR USES
WO2021173812A1 (en) * 2020-02-28 2021-09-02 Aligos Therapeutics, Inc. Methods and compositions for targeting pd-l1
KR20230016623A (ko) * 2020-04-30 2023-02-02 세카나 파머씨티컬스 지엠비에이치 엔 씨오. 케이지 Pd-1-특이적 안티센스 올리고뉴클레오티드 및 요법에서의 이의 용도
EP4211241A1 (en) * 2020-09-10 2023-07-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of splice switching oligonucleotides for exon skipping-mediated knockdown of nf-kb components in b cells
WO2022084389A1 (en) * 2020-10-20 2022-04-28 Immunoa Pte. Ltd. Modified immune cells
CN116670282A (zh) 2020-12-22 2023-08-29 豪夫迈·罗氏有限公司 靶向xbp1的寡核苷酸
CN115216474B (zh) * 2021-04-15 2025-09-30 武汉大学 促进pd-l1外显子3跳跃的反义寡核苷酸及其应用
EP4074835A1 (en) * 2021-04-15 2022-10-19 Deutsches Krebsforschungszentrum - Stiftung des öffentlichen Rechts / Universität Heidelberg H-1 pv expressing rnai effectors
WO2023073709A1 (en) * 2021-10-27 2023-05-04 Hadasit Medical Research Services & Development Ltd. Nucleic acid agents modulating pd-1 isoforms
CN118956872A (zh) * 2024-08-16 2024-11-15 首都医科大学附属北京朝阳医院 IFN-γ mRNA的反义寡核苷酸及其应用和药用组合物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6566132B1 (en) 2001-04-26 2003-05-20 Isis Pharmaceuticals, Inc. Antisense modulation of Interferon gamma receptor 1 expression
US8501704B2 (en) * 2005-11-08 2013-08-06 Sarepta Therapeutics, Inc. Immunosuppression compound and treatment method
AU2006311586A1 (en) * 2005-11-08 2007-05-18 Avi Biopharma, Inc. Immunosuppression compound and treatment method
LT2735568T (lt) 2006-05-10 2017-11-27 Sarepta Therapeutics, Inc. Oligonukleotido analogai, turintys katijonines jungtis tarp subvienetų
EP2295543A1 (en) * 2009-09-11 2011-03-16 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Method for the preparation of an influenza virus
WO2011120101A1 (en) 2010-04-01 2011-10-06 The University Of Queensland Small rna molecules and methods of use
WO2013135830A1 (en) * 2012-03-14 2013-09-19 Ruprecht-Karls-Universität Heidelberg Epigenetic signatures as marker for cardiomyopathies and myocardial insufficiencies
US20150017136A1 (en) * 2013-07-15 2015-01-15 Cellectis Methods for engineering allogeneic and highly active t cell for immunotherapy
WO2014078749A1 (en) 2012-11-15 2014-05-22 The Regents Of The University Of California Splice modulating oligonucleotides that inhibit cancer
EP2931893A1 (en) 2012-12-13 2015-10-21 Universität Leipzig T-cell modulation by exon skipping
CN103820454B (zh) * 2014-03-04 2016-03-30 上海金卫生物技术有限公司 CRISPR-Cas9特异性敲除人PD1基因的方法以及用于特异性靶向PD1基因的sgRNA
SG11201608701QA (en) * 2014-04-18 2016-11-29 Editas Medicine Inc Crispr-cas-related methods, compositions and components for cancer immunotherapy
WO2016138278A2 (en) * 2015-02-27 2016-09-01 Idera Pharmaceuticals, Inc. Compositions for inhibiting checkpoint gene expression and uses thereof
BR112017020750A2 (en) * 2015-03-27 2018-06-26 President And Fellows Of Harvard College modified t-cells and methods of producing and using them
MX2017015239A (es) * 2015-05-29 2018-02-19 Juno Therapeutics Inc Composicion y metodos para regular interacciones inhibitorias en celulas geneticamente modificadas.
WO2017093969A1 (en) * 2015-12-04 2017-06-08 Novartis Ag Compositions and methods for immunooncology

Also Published As

Publication number Publication date
JP7284718B2 (ja) 2023-05-31
US20200377883A1 (en) 2020-12-03
AU2018291556A1 (en) 2020-01-02
WO2019004939A1 (en) 2019-01-03
AU2018291556B2 (en) 2021-12-09
KR20200035937A (ko) 2020-04-06
SG11201911704UA (en) 2020-01-30
EP3645724A4 (en) 2021-07-21
US12188016B2 (en) 2025-01-07
JP2020530981A (ja) 2020-11-05
CA3066035A1 (en) 2019-01-03
CN111630167A (zh) 2020-09-04
CN111630167B (zh) 2024-08-09
EP3645724A1 (en) 2020-05-06

Similar Documents

Publication Publication Date Title
IL288956A (en) RN" A building
SA519402143B1 (ar) مترافقات أوليجومرات تخطي الإكسون للحَثَل العَضَلِيّ
MY185390A (en) Antisense nucleic acids
SG11202005860SA (en) Amplifying, generating, or certifying randomness
IL272838A (en) Peptidase-specific ubiquitin inhibition 30
EA201991450A1 (ru) Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии
MX2020012133A (es) Complejo que contiene oligonucleotido que tiene actividad potenciadora inmune, y uso del mismo.
EA201892467A1 (ru) Олигонуклеотидные аналоги, нацеленные на lmna человека
PH12016501761A1 (en) Antisense nucleic acids
MX2022003859A (es) Compuestos para usarse en el tratamiento o prevencion de retinitis pigmentosa.
MX2019006882A (es) Conjugados de oligomeros de omision de exon para distrofia muscular.
EP3995581A3 (en) Oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders
MX2018016052A (es) Oligomeros de omision de exon para distrofia muscular.
MX363846B (es) Moduladores de oligonucleotido de linfoma linfocitico cronico/linfoma de celulas b 11a (bcl11a) y sus usos.
SG11201911704UA (en) Antisense oligonucleotides for modulating the function of a t cell
MX2018002665A (es) Combinacion que comprende oligonucleotidos inmunoestimulantes.
IL277921A (en) RNA new small operators
MX2020005754A (es) Oligonucleotidos gapmeros que comprenden un enlace internucleosido fosforoditioato.
ZA201906271B (en) Acylnucleoside phosphonates, prodrugs thereof and use thereof as medicament
EP3584319A4 (en) SINGLE-STRAND OLIGONUCLEOTIDE
MX2020003640A (es) Lamina de acero electrico de grano orientado.
EP3130597A4 (en) Oligonucleotide having non-natural nucleotide at 5'-terminal thereof
MX2017001369A (es) Aleaciones de rodio.
MX362688B (es) Elemento de purga de gas y línea de alimentación de gas asociada.
SG11202111525XA (en) Stable targeted integration